Publications & Works

Publication Network

Published journal articles indexed by SCI, SSCI, and AHCI

Post-induction lymph node delineation in nasopharyngeal cancer: A single-center experience.

Sari S., YİĞİT E., YAZICI G., GÜLLÜ İ. H., AKSOY S., ÖZYİĞİT G., et al.
Head & neck, vol.45, no.3, pp.612-619, 2023 (SCI-Expanded) Sustainable Development identifier identifier identifier

Cancer incidence in Behcet's Disease.

Guven D. C., Bolek E. C., Altintop S. E., Celikten B., Aktas B. Y., Kiraz S., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.38, no.15, 2020 (SCI-Expanded) identifier

Neoadjuvant Chemotherapy Improves Survival in Patients with Locally Advanced Nasopharyngeal Carcinoma

Basaran H., CENGİZ M., YAZICI G., Susulu N., AKSOY S., HOŞAL A. Ş., et al.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, vol.29, no.3, pp.176-185, 2019 (SCI-Expanded) Creative Commons License identifier identifier

Detection of O6-methylguanine-DNA methyltransferase gene promoter region methylation pattern using pyrosequencing and the effect of methylation pattern on survival, recurrence, and chemotherapy sensitivity in patients with laryngeal cancer

Celebi O. O., Tezel G. G., Hosal A. S., CENGİZ M., GÜLLÜ İ. H., HAYRAN K. M.
PATHOLOGY RESEARCH AND PRACTICE, vol.212, no.5, pp.456-462, 2016 (SCI-Expanded) identifier identifier identifier

Successful treatment of benign metastasizing leiomyoma with oral alternated chemotherapeutic agents

Sarici F., Babacan T., Altundag K., Balakan O., Gullu I.
JOURNAL OF BUON, vol.18, no.3, pp.799, 2013 (SCI-Expanded) identifier identifier identifier

Long-term advanced cholangiocarcinoma survivor with single-agent capecitabine

Petekkaya I., Gezgen G., Roach E. C., Solak M., Altundag K., Gullu I.
JOURNAL OF BUON, vol.17, no.4, pp.796, 2012 (SCI-Expanded) identifier identifier identifier

SALVAGE REIRRADIATON WITH STEREOTACTIC BODY RADIOTHERAPY FOR LOCALLY RECURRENT HEAD-AND-NECK TUMORS

CENGİZ M., ÖZYİĞİT G., YAZICI G., DOĞAN A., YILDIZ F., Zorlu F., et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol.81, no.1, pp.104-109, 2011 (SCI-Expanded) identifier identifier identifier

Clinicopathologic evaluation of non-Hodgkin lymphoma (NHL): A single centre experience

Kilickap S., Barista I., Turkmen E., Dizdar O., Aksoy S., Turker A., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.26, no.15, 2008 (SCI-Expanded) identifier

Potential molecular targeted therapies in the management of the basal-like subtype of breast cancer

KURT M., Harputluoglu H., ŞENER DEDE D., GÜLLÜ İ. H., Altundag K.
BREAST, vol.16, no.2, pp.111-112, 2007 (SCI-Expanded) Sustainable Development identifier identifier identifier

Mucosa associated lymphoid tissue lymphoma of the sub mandibular gland presenting with relapse in the lacrimal gland

KURT M., Shorbagi A., ALTUNDAĞ M. K., AKYÖN YILMAZ Y., DİZDAR Ö., GÜLLÜ İ. H.
Leukemia, vol.47, pp.1982-1984, 2006 (SCI-Expanded)

Complications due to late diagnosis of celiac disease with co-existing plasma cell dyscrasia in an elderly patient

Cankurtaran M., Ulger Z., Dogan S., Yavuz B., Halil M., Gullu I., et al.
AGING CLINICAL AND EXPERIMENTAL RESEARCH, vol.18, no.1, pp.75-77, 2006 (SCI-Expanded) Sustainable Development identifier identifier identifier

Peripheral T-cell lymphoma and Job's syndrome

Onal I., Kurt M., Altundag K., Aksoy S., Dincer M., Gullu I.
MEDICAL ONCOLOGY, vol.23, no.1, pp.141-144, 2006 (SCI-Expanded) identifier identifier identifier

Possible association between Budd-Chiari syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia

Kurt M., Shorbagi A., Altundag K., Elkiran T., Gullu I., Kansu E.
AMERICAN JOURNAL OF HEMATOLOGY, vol.80, no.3, pp.213-215, 2005 (SCI-Expanded) identifier identifier identifier

Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: Results of single-center study of 45 patients

Altundag O., Gullu I., Altundag K., Yalcin S., Ozyar E., Cengiz M., et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, vol.27, no.1, pp.15-21, 2005 (SCI-Expanded) identifier identifier identifier

Acute tumor lysis syndrome triggered by zoledronic acid in a patient with metastatic lung adenocarcinoma

Kurt M., Onal I., Elkiran T., Altun B., Altundag K., Gullu I.
MEDICAL ONCOLOGY, vol.22, no.2, pp.203-206, 2005 (SCI-Expanded) identifier identifier identifier

Calcium and vitamin D supplementation during bisphosphonate administration may increase osteoclastic activity in patients with bone metastasis

Altundag O., Altundag K., Silay Y., Gunduz M., Demircan K., Gullu I.
MEDICAL HYPOTHESES, vol.63, no.6, pp.1010-1013, 2004 (SCI-Expanded) Sustainable Development identifier identifier

Hypocalcemic effect of zoledronic acid or other bisphosphonates may contribute to their antiangiogenic properties

Aksoy S., Abali H., Dincer M., Kilickap S., Gullu I., Tekuzman G.
MEDICAL HYPOTHESES, vol.62, no.6, pp.942-944, 2004 (SCI-Expanded) identifier identifier identifier

Salvage ifosfamide-doxorubicin chemotherapy in patients with recurrent nasopharyngeal carcinoma pretreated with cisplatin-based chemotherapy

Altundag K., Aksoy S., Gullu I., Altundag O., Ozyar E., Yalcin S., et al.
MEDICAL ONCOLOGY, vol.21, no.3, pp.211-215, 2004 (SCI-Expanded) identifier identifier identifier

Biweekly irinotecan plus bolus 5-fluorouracil and folinic acid in patients with advanced stage colorectal cancer

Yalcin S., Oksuzoglu B., Tekuzman G., Engin H., Celik I., Turker A., et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol.33, no.11, pp.580-583, 2003 (SCI-Expanded) Sustainable Development identifier identifier identifier

Weekly irinotecan in patients with metastatic colorectal cancer failing 5-fluorouracil-based chemotherapy: Efficacy and prognostic factors

Karaoglu A., Yalcin S., Tekuzman G., Kars A., Celik I., Guler N., et al.
TUMORI, vol.89, no.2, pp.141-145, 2003 (SCI-Expanded) Sustainable Development identifier identifier identifier

Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy

Barista I., Tekuzman G., Yalcin S., Gullu I., Guler N., Ozisik Y., et al.
JOURNAL OF SURGICAL ONCOLOGY, vol.73, no.1, pp.12-16, 2000 (SCI-Expanded) identifier

Efficacy of sulbactam-ampicillin for the treatment of severe diabetic foot infections

Akova M., Ozcebe O. İ., Gullu I., Unal S., GUR D., AKALIN S., et al.
JOURNAL OF CHEMOTHERAPY, vol.8, no.4, pp.284-289, 1996 (SCI-Expanded) Sustainable Development identifier identifier identifier

Articles Published in Other Journals

Outcome of Elderly Nasopharyngeal Carcinoma Patients: A Single Center Study

Basaran H., CENGİZ M., YAZICI G., Ozdemir Y., SÜTAY SÜSLÜ N., GÜLLÜ İ. H., et al.
EUROPEAN JOURNAL OF THERAPEUTICS, vol.26, no.2, pp.129-134, 2020 (ESCI) identifier

The Synergistic Effect of Immune Checkpoint Blockade and Radiotherapy in Recurrent/Metastatic Sinonasal Cancer

YAZICI G., GÜLLÜ İ. H., CENGİZ M., ELMALI DOĞAN A., YILMAZ M. T., AKSOY S., et al.
Cureus, vol.10, pp.3519, 2018 (ESCI) Creative Commons License Sustainable Development identifier identifier

How would you manage a rare cause of haemoptysis?

Ulubay G., Gorek A., Akcay S., Gullu I.
BREATHE, vol.3, no.2, pp.203-205, 2006 (ESCI) Creative Commons License identifier

Metastatic biology

GÜLLÜ İ. H., Akalin I.
UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, vol.4, no.4, pp.16-19, 2005 (ESCI) Sustainable Development identifier identifier identifier

Refereed Congress / Symposium Publications in Proceedings

Baş-Boyun Melanomlarında Radyoterapi Sonuçlarımız

YÜCE SARI S., YAZICI G., CENGİZ M., YILMAZ M. T., AKSOY S., GÜLLÜ İ. H., et al.
13. ULUSAL RADYASYON ONKOLOJİSİ KONGRESİ, Turkey, 27 April - 01 May 2018

Adjuvan Yoğunluk Ayarlı Radyoterapi Uygulanan Baş-Boyun Kanserli Olgularda Tedavi Sonuçlarımız.

YÜCE SARI S., CENGİZ M., YAZICI G., ELMALI DOĞAN A., BEDÜK Ç. S., GÜLLÜ İ. H., et al.
13.Ulusal Radyasyon Onkolojisi Kongresi, Turkey, 27 April - 01 May 2018 Sustainable Development

Definitif Radyoterapi Uygulanan Lokal İleri Evre Larinks Kanserli Hastalarda Hematolojik Parametrelerin Sağkalım Üzerine Prognostik Etkisi

YÜCE SARI S., CENGİZ M., GÜLTEKİN M., SÜSLÜ N., YAZICI G., HAYRAN K. M., et al.
22. UKK, Turkey, 19 - 23 April 2017 Sustainable Development

Survival and Larynx Preservation Rates after Definitive Radiotherapy A Single Center Experience

CENGİZ M., YÜCE SARI S., GÜLTEKİN M., SÜSLÜ N., AKSOY S., KUŞCU O., et al.
ECHNO 2016, Budapest, Hungary, 7 - 10 September 2016

The impact of the total size of lesions in multifocal multicentric breast cancer on survival

Karakaş Y., DİZDAR Ö., Akın S., ATEŞ Ö., ŞENDUR M. A. N., AKSOY S., et al.
2016 ASCO Annual Meeting, 29 May - 03 June 2016 Sustainable Development

Modified docetaxel cisplatin and fluorouracil therapy as a first line treatment for patients with recurrent metastatic squamous cell carcinoma of the head and neck cancer a retrospective study

DEMİRCİ N., AKSOY S., ÖZDEMİR N., Babacan T., ERDEM G. U., BOZKAYA Y., et al.
2016 ASCO Annual Meeting, 29 May - 03 June 2016 Sustainable Development

Radiation Therapy Results of Patients With Adenoid Cystic Carcinoma

GÜLTEKİN M., CENGİZ M., Sari S. Y., HOŞAL Ş., YAZICI G., SÜSLÜ N., et al.
57th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO), San-Antonio, Northern Mariana Islands, 18 - 21 October 2015, vol.93 Creative Commons License identifier

Comparison of three different induction regimen in nasopharyngeal cancer: CF versus DC versus DCF.

Kertmen N., Aksoy S., Cengiz M., Yazici G., Keskin O., Babacan T., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32 Sustainable Development identifier

Outcomes of patients with HER2-negative breast cancer with central nervous system metastasis treated with capecitabine.

Altundag K., Aksoy S., Sendur M. A. N., Guler E. N., Gullu I. H., Ozisik Y. Y.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31 Sustainable Development identifier

Early stage "T2N0" breast cancer: Does it consist two different "T2" stages?

Arslan C., Sahin U., Kizilarslanoglu C., Solak M., Gullu I. H., Ozisik Y., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31 Sustainable Development identifier

Comparison of ER, PR, HER2 in primary and paired relapsed/metastatic lesions of metastatic breast cancer patients

SARI E., Guler G., HAYRAN K. M., Altundag K., GÜLLÜ İ. H., Ozisik Y.
45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 29 May - 02 June 2009, vol.27 Sustainable Development identifier

Comparison of serum levels of CEA and CA 15-3 in triple-negative breast cancer at the time of metastases and serum levels at the time of first diagnosis

Dede D. S., Aksoy S., Bulut N., Dizdar O., Arik Z., Gullu I., et al.
45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 29 May - 02 June 2009, vol.27 Sustainable Development identifier

Characteristics of breast cancer patients with central nervous system metastases and factors associated with survival after development of central nervous system metastasis

Harputluoglu H., Dizdar O., Aksoy S., Kilickap S., Dede D. S., Ozisik Y., et al.
30th Annual San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 13 - 16 December 2007, vol.106 Sustainable Development identifier

Serum LDH level is a prognostic factor in locoregionally advanced nasopharyngeal carcinoma (NPC) patients treated with chemoradiotherapy

Turen S., Ozyar E., Altundag K., Gullu I., Atahan I.
23rd Annual Meeting of the European-Society-for-Therapeutic-Radiology-and-Oncology (ESTRO 23), Amsterdam, Netherlands, 24 - 28 October 2004, vol.73 identifier

Clinicopathological features and outcome of primary gastric lymphoma: A series of 73 cases

Oyan B., Tekuzman G., Barista I., Kars A., Turker A., Ozisik Y., et al.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22 identifier